Though life-changing medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are only approved right now for type 2 diabetes, a growing body of evidence shows the potential benefits for people living with type 1 diabetes as well. Promising results from a new study on tirzepatide for people with type 1 diabetes were presented recently at the ATTD 2025 conference in Amsterdam. During the study, 84 adults with type 1 diabetes and overweight or obesity were given tirzepatide off-label. After 21 months, participants experienced 23% weight loss and sustained improvements in glucose management.
New-onset diabetes after SARS-CoV-2 infection has been documented.1-4 Milder Omicron variant infection and booster vaccination may mitigate risk, but most available studies predate Omicron emergence and booster rollout.1-3 We estimated risk of new-onset type 2 diabetes (T2D) after SARS-CoV-2 infection among boosted adults during Delta- and Omicron-predominant transmission in Singapore.
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the proportion of adolescents living with overweight or obesity in England has increased by 50% from 2008-2010 (22%) to 2021-2023 (33%). The research, presented in two studies, is by Dr Dinesh Giri, Consultant Paediatric Endocrinologist, Bristol Royal Hospital for Children and Honorary Senior Lecturer, University of Bristol, Bristol, UK, and Dr Senthil Senniappan, Consultant Paediatric Endocrinologist, Alder Hey Children’s Hospital, Liverpool, UK, and colleagues.
New-onset diabetes after SARS-CoV-2 infection has been documented.1-4 Milder Omicron variant infection and booster vaccination may mitigate risk, but most available studies predate Omicron emergence and booster rollout.1-3 We estimated risk of new-onset type 2 diabetes (T2D) after SARS-CoV-2 infection among boosted adults during Delta- and Omicron-predominant transmission in Singapore.
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the proportion of adolescents living with overweight or obesity in England has increased by 50% from 2008-2010 (22%) to 2021-2023 (33%). The research, presented in two studies, is by Dr Dinesh Giri, Consultant Paediatric Endocrinologist, Bristol Royal Hospital for Children and Honorary Senior Lecturer, University of Bristol, Bristol, UK, and Dr Senthil Senniappan, Consultant Paediatric Endocrinologist, Alder Hey Children’s Hospital, Liverpool, UK, and colleagues.
Though life-changing medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are only approved right now for type 2 diabetes, a growing body of evidence shows the potential benefits for people living with type 1 diabetes as well. Promising results from a new study on tirzepatide for people with type 1 diabetes were presented recently at the ATTD 2025 conference in Amsterdam. During the study, 84 adults with type 1 diabetes and overweight or obesity were given tirzepatide off-label. After 21 months, participants experienced 23% weight loss and sustained improvements in glucose management.
New-onset diabetes after SARS-CoV-2 infection has been documented.1-4 Milder Omicron variant infection and booster vaccination may mitigate risk, but most available studies predate Omicron emergence and booster rollout.1-3 We estimated risk of new-onset type 2 diabetes (T2D) after SARS-CoV-2 infection among boosted adults during Delta- and Omicron-predominant transmission in Singapore.
Gestational diabetes mellitus (GDM) is a common disorder of glucose metabolism that is detected for the first time in pregnancy; its global prevalence is estimated to be 15.8%. The main risk factors for the disease are overweight and obesity (body mass index, BMI 25–29.9 kg/m2 and ≥30 kg/m2), and in Finland in 2021, almost 40% of pregnant women were with overweight . GDM predisposes women to complications for both mother and child, including preeclampsia, complications at delivery, inclusive of the need for caesarean section, shoulder dystocia, physical birth trauma and admission to the neonatal intensive care unit, and later in life to an increased risk for type 2 diabetes.
Bariatric surgery, once the criterion standard in obesity treatment, has a small but concerning association with increased suicidality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), originally developed to treat diabetes, now provide substantial efficacy in the treatment of obesity. However, concerns of risk of suicidality with these medicines have been raised.
The incidence of metabolic dysfunction-associated steatohepatopathy (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has risen globally in tandem with the increase in obesity, about 30 % of the general population has MASLD. This updated terminology more accurately characterizes liver disease linked to identifiable metabolic dysfunction. According to the new definition, MASLD is characterized by hepatic steatosis and at least one of the following three criteria: overweight/obesity, T2DM, or indications of metabolic dysfunction. In addition to these comorbidities, MASLD is closely related to insulin resistance. Metabolic syndrome includes three key components: abdominal obesity, hypertriglyceridemia, low HDL cholesterol, hypertension, and/or hyperglycemia.
Though life-changing medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are only approved right now for type 2 diabetes, a growing body of evidence shows the potential benefits for people living with type 1 diabetes as well. Promising results from a new study on tirzepatide for people with type 1 diabetes were presented recently at the ATTD 2025 conference in Amsterdam. During the study, 84 adults with type 1 diabetes and overweight or obesity were given tirzepatide off-label. After 21 months, participants experienced 23% weight loss and sustained improvements in glucose management.
New-onset diabetes after SARS-CoV-2 infection has been documented.1-4 Milder Omicron variant infection and booster vaccination may mitigate risk, but most available studies predate Omicron emergence and booster rollout.1-3 We estimated risk of new-onset type 2 diabetes (T2D) after SARS-CoV-2 infection among boosted adults during Delta- and Omicron-predominant transmission in Singapore.
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that the proportion of adolescents living with overweight or obesity in England has increased by 50% from 2008-2010 (22%) to 2021-2023 (33%). The research, presented in two studies, is by Dr Dinesh Giri, Consultant Paediatric Endocrinologist, Bristol Royal Hospital for Children and Honorary Senior Lecturer, University of Bristol, Bristol, UK, and Dr Senthil Senniappan, Consultant Paediatric Endocrinologist, Alder Hey Children’s Hospital, Liverpool, UK, and colleagues.
